|
US20030022311A1
(en)
|
1996-05-21 |
2003-01-30 |
Dunnington Damien D. |
Human CIS protein
|
|
US6323317B1
(en)
|
1996-11-01 |
2001-11-27 |
The Walter And Eliza Hall Institute Of Medical Research |
Therapeutic and diagnostics proteins comprising a SOCS box
|
|
ATE323756T1
(de)
|
1997-04-30 |
2006-05-15 |
Hans Klingemann |
Natürliche killerzelllinien und verfahren zu ihrer verwendung
|
|
EP1958962A3
(en)
|
1997-06-12 |
2013-05-01 |
Novartis International Pharmaceutical Ltd. |
Artificial antibody polypeptides
|
|
AU2003218456A1
(en)
*
|
2002-04-01 |
2003-10-20 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to gmad
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
US20050271660A1
(en)
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
|
JP2008522951A
(ja)
|
2004-07-19 |
2008-07-03 |
ベイラー・カレツジ・オブ・メデイシン |
サイトカインシグナル伝達調節物質の調節および免疫療法のための応用
|
|
US7863240B2
(en)
|
2004-10-08 |
2011-01-04 |
Enzo Therapeutics, Inc. |
Methods and uses of leptin in hepatocellular carcinoma
|
|
US7868159B2
(en)
|
2005-06-23 |
2011-01-11 |
Baylor College Of Medicine |
Modulation of negative immune regulators and applications for immunotherapy
|
|
EP1940460A4
(en)
|
2005-10-27 |
2009-08-12 |
Biogen Idec Inc |
OLIGOD DRO CYTEN MYELIN GLYCOPROTEIN COMPOSITIONS AND USES THEREOF
|
|
MX2008014710A
(es)
*
|
2006-05-19 |
2009-02-12 |
Amgen Inc |
Anticuerpos para coronavirus del sars.
|
|
CA2742969A1
(en)
*
|
2008-11-07 |
2010-05-14 |
Fabrus Llc |
Anti-dll4 antibodies and uses thereof
|
|
US20120192298A1
(en)
|
2009-07-24 |
2012-07-26 |
Sigma Aldrich Co. Llc |
Method for genome editing
|
|
WO2012078540A1
(en)
|
2010-12-08 |
2012-06-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Modulating immune cell activity using cytokine-induced src homology 2 and/or high temperature requirement a-1
|
|
DK2956175T3
(da)
*
|
2013-02-15 |
2017-11-27 |
Univ California |
Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
|
|
CA2932547C
(en)
*
|
2014-01-06 |
2023-05-23 |
F. Hoffmann-La Roche Ag |
Monovalent blood brain barrier shuttle modules
|
|
WO2015121454A1
(en)
*
|
2014-02-14 |
2015-08-20 |
Cellectis |
Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
|
|
JP6681837B2
(ja)
|
2014-03-11 |
2020-04-15 |
セレクティスＣｅｌｌｅｃｔｉｓ |
同種移植に適合するｔ細胞を作製するための方法
|
|
DK3143134T3
(da)
|
2014-05-15 |
2021-01-04 |
Nat Univ Singapore |
Modificerede, naturlige dræberceller og anvendelser deraf
|
|
US20170101466A1
(en)
*
|
2014-06-03 |
2017-04-13 |
Masahisa Handa |
Anti-blys antibodies
|
|
CN116059378A
(zh)
|
2014-12-10 |
2023-05-05 |
明尼苏达大学董事会 |
用于治疗疾病的遗传修饰的细胞、组织和器官
|
|
CN116199790A
(zh)
|
2015-02-10 |
2023-06-02 |
米纳瓦生物技术公司 |
人源化抗MUCl*抗体
|
|
US10100118B2
(en)
*
|
2015-04-08 |
2018-10-16 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind CD123
|
|
EP3356415B1
(en)
*
|
2015-09-29 |
2024-05-01 |
Amgen Inc. |
Asgr inhibitors for reduzing cholesterol levels
|
|
EP3423580A1
(en)
|
2016-03-04 |
2019-01-09 |
Editas Medicine, Inc. |
Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
|
|
WO2018064602A1
(en)
|
2016-09-30 |
2018-04-05 |
Baylor College Of Medicine |
Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease
|
|
AU2017347854B2
(en)
|
2016-10-27 |
2022-12-08 |
Intima Bioscience, Inc. |
Viral methods of T cell therapy
|
|
TN2019000164A1
(en)
|
2016-11-23 |
2020-10-05 |
Bioverativ Therapeutics Inc |
Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x
|
|
US20180100016A1
(en)
|
2016-12-22 |
2018-04-12 |
Xiaotong Song |
Use of car-modified human natural killer cells to treat cancer
|
|
CA3048224A1
(en)
*
|
2016-12-23 |
2018-06-28 |
Bluefin Biomedicine, Inc. |
Anti-sez6l2 antibodies and antibody drug conjugates
|
|
JP2020503043A
(ja)
|
2016-12-30 |
2020-01-30 |
セルラリティ インコーポレイテッド |
遺伝子改変されたナチュラルキラー細胞
|
|
BR112019019917A2
(pt)
*
|
2017-03-27 |
2020-04-22 |
Nat Univ Singapore |
receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
WO2018225732A1
(ja)
*
|
2017-06-05 |
2018-12-13 |
国立大学法人三重大学 |
Ｍａｇｅ－ａ４由来ペプチドを認識する抗原結合性タンパク質
|
|
WO2018231759A1
(en)
*
|
2017-06-12 |
2018-12-20 |
Obsidian Therapeutics, Inc. |
Pde5 compositions and methods for immunotherapy
|
|
EP3645021A4
(en)
*
|
2017-06-30 |
2021-04-21 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
|
WO2019101998A1
(en)
*
|
2017-11-24 |
2019-05-31 |
Onkimmune Limited |
Modified natural killer cells and natural killer cell lines targetting tumour cells
|
|
CN112020518A
(zh)
*
|
2018-02-01 |
2020-12-01 |
辉瑞公司 |
靶向cd70的嵌合抗原受体
|
|
MX2020009272A
(es)
|
2018-03-06 |
2021-01-08 |
Univ Pennsylvania |
Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.
|
|
CN110351878B
(zh)
*
|
2018-04-04 |
2023-07-14 |
华为技术有限公司 |
一种随机接入处理方法和相关设备
|
|
MX2020012028A
(es)
|
2018-05-11 |
2021-03-29 |
Crispr Therapeutics Ag |
Metodos y composiciones para tratar el cancer.
|
|
CA3104868A1
(en)
|
2018-07-09 |
2020-01-16 |
Surrozen, Inc. |
Tissue-specific wnt signal enhancing molecules and uses thereof
|
|
AU2019337603B2
(en)
*
|
2018-09-13 |
2026-03-05 |
Nkarta, Inc. |
Natural killer cell compositions and immunotherapy methods for treating tumors
|
|
AU2020288829A1
(en)
|
2019-06-04 |
2021-12-02 |
Nkarta, Inc. |
Combinations of engineered natural killer cells and engineered T cells for immunotherapy
|
|
WO2020261219A1
(en)
|
2019-06-27 |
2020-12-30 |
Crispr Therapeutics Ag |
Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
|
|
KR20220051401A
(ko)
|
2019-09-06 |
2022-04-26 |
크리스퍼 테라퓨틱스 아게 |
배양 중 개선된 지속성을 갖는 유전적으로 조작된 t 세포
|
|
KR20220097985A
(ko)
|
2019-11-13 |
2022-07-08 |
크리스퍼 테라퓨틱스 아게 |
Car-t 세포의 제조 방법
|
|
WO2021095010A1
(en)
|
2019-11-13 |
2021-05-20 |
Crispr Therapeutics Ag |
Renal cell carcinoma (rcc) therapy using genetically engineered t cells targeting cd70
|
|
IL292467A
(en)
|
2019-11-13 |
2022-06-01 |
Crispr Therapeutics Ag |
Treatment of hematopoietic cell cancers using genetically engineered t cells targeting cd70
|
|
JP2023502780A
(ja)
|
2019-11-25 |
2023-01-25 |
ケーエスキュー セラピューティクス， インコーポレイテッド |
腫瘍浸潤リンパ球の活性化及び増殖方法
|
|
WO2021157601A1
(ja)
|
2020-02-03 |
2021-08-12 |
国立大学法人東海国立大学機構 |
がんを有する対象においてがんを処置することに用いるための抗ｍｅｆｌｉｎ抗体、および当該抗体を含む医薬組成物
|
|
IL298136A
(en)
*
|
2020-05-13 |
2023-01-01 |
Bonum Therapeutics Inc |
Preparations of protein complexes and methods of using them
|
|
AU2021286655A1
(en)
|
2020-06-12 |
2023-01-05 |
Nkarta, Inc. |
Genetically modified natural killer cells for CD70-directed cancer immunotherapy
|
|
KR20230041819A
(ko)
|
2020-07-29 |
2023-03-24 |
얀센 바이오테크 인코포레이티드 |
Hla-g 항원-결합 도메인을 포함하는 단백질 및 이의 용도
|
|
CN116322716A
(zh)
|
2020-09-23 |
2023-06-23 |
克里斯珀医疗股份公司 |
Regnase-1和/或TGFBRII被破坏的基因工程化T细胞具有改善的功能性和持久性
|
|
EP4255453A4
(en)
*
|
2020-12-03 |
2025-03-26 |
Nkarta, Inc. |
Methods for manipulating immune cells for increased potency and persistence, as well as uses of engineered cells in immunotherapy
|
|
US20220378829A1
(en)
|
2021-05-12 |
2022-12-01 |
Crispr Therapeutics Ag |
Genetically engineered immune cells targeting cd70 for use in treating solid tumors
|
|
AR125851A1
(es)
|
2021-05-12 |
2023-08-16 |
Crispr Therapeutics Ag |
Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en el tratamiento de neoplasias malignas hematopoyéticas
|
|
JP2025508050A
(ja)
|
2022-03-07 |
2025-03-21 |
ンカルタ・インコーポレイテッド |
Ｃｄ７０指向性がん免疫療法のための多重遺伝子編集細胞
|